Highlights

  • Uscom Limited sold all subsidiaries for $2.59 million, transforming into an ASX-listed shell company.
  • Transaction proceeds extinguished related-party debt, generating a $2.35 million pre-tax disposal gain.
  • ASX suspension remains in place, with a two-year compliance window expiring September 2027

Uscom Limited (ASX:UCM) was, until late 2025, one of Australia's few publicly listed medical device companies with a genuinely global operational footprint. Founded and built around proprietary non-invasive cardiovascular monitoring technology — particularly its flagship USCOM device, which provides real-time haemodynamic monitoring without the need for invasive procedures — the company had established a commercial presence across Australia, the United States, the United Kingdom, Europe, Asia, and China.

The company's technology addressed a meaningful clinical need: rapid, accurate, and non-invasive assessment of cardiac output and other haemodynamic parameters in critically ill patients, emergency departments, intensive care units, and outpatient settings. Uscom's devices were used by clinicians to guide fluid management, ventilation, and drug therapy decisions — applications with clear value in emergency and critical care medicine.

The Sale of All Subsidiaries: A Definitive Corporate Transformation

The defining event of Uscom's recent history was the shareholder-approved sale of all its wholly owned subsidiaries to AXO Medtech VCC (AXO) for total consideration of $2.59 million. This transaction was approved by shareholders at the Annual General Meeting held on 7 November 2025 and completed on 30 November 2025, when control formally passed to the purchaser and all assets and liabilities were transferred.

The subsidiaries disposed of in this transaction were substantial — representing the entirety of Uscom's international trading operations. They included Uscom Inc. (USA), Uscom Medical Ltd (UK), Uscom Kft (Hungary), Uscom SNG Pte. Ltd (Singapore), Beijing Uscom Consulting Co. Ltd (China), Uscom Australia Pty Ltd, and Beijing Uscom MedTech Co. Ltd. Together, these entities comprised Uscom's commercial infrastructure across every market in which the company had operated.

The consideration of $2.591 million was structured uniquely. Rather than a cash payment, the sale proceeds were applied to discharge related-party loans: $1.59 million (including accrued interest) owed to Professor Rob Phillips (Executive Chairman of Uscom), and $1.0 million owed to Jetan Pty Limited (a substantial shareholder of the company, with $700,000 of this amount drawn down during the reporting period). This structure meant that the transaction simultaneously divested all operating subsidiaries and substantially extinguished the company's related-party debt obligations.

The pre-tax gain on disposal recognised in the accounts was $2,353,063, representing the difference between the $2.591 million consideration received, the net assets disposed of ($416,428), and the recycling of foreign currency translation reserves ($178,491) on disposal.

ASX Suspension: The Regulatory Context

On 29 September 2025 — before the subsidiary sale was completed — Uscom Limited was suspended from quotation on the Australian Securities Exchange. The ASX determined that the company did not satisfy Listing Rule 12.2, which requires that an entity's financial condition be adequate to warrant continued quotation. The ASX reached this determination with reference to the disclaimer of opinion contained in the auditor's report for the year ended 30 June 2025 — the most serious form of audit qualification, indicating the auditor was unable to obtain sufficient evidence to form an opinion on the financial statements.

The company remains suspended from trading as at the date of the half-year report (27 February 2026). However, in a significant post-balance-date development, the ASX granted Uscom a period of two years — expiring 29 September 2027 — within which to satisfy the requirements necessary to remain listed. If those requirements are not met within that timeframe, the company may be removed from the official list of the ASX.

This two-year window is the critical regulatory lifeline for Uscom's future as a listed entity, and it defines the company's near-term strategic imperative.

Financial Performance: Half-Year to 31 December 2025

The financial results for the six months to 31 December 2025 reflect a company in profound transition. Understanding these numbers requires recognising that from 1 July to 30 November 2025, Uscom continued trading across its global operations, while December 2025 represented a period of completing the asset disposals approved by shareholders on 7 November.

Revenue and other income for the half-year totalled $1,174,155 — a 38% decline from the prior corresponding period — directly attributable to the cessation of overseas operations following the 30 November disposal. Sales revenue from continuing operations was $502,000 (versus $455,457 in the prior period), with grants of $190,000 and interest income of $1,513. Revenue from discontinued operations (the overseas subsidiaries) contributed $301,448 in sales, alongside $179,120 in miscellaneous income.

The net gain for the period was $821,243, driven almost entirely by the $2,353,063 gain on disposal of subsidiaries. Excluding this non-recurring gain, the company recorded a combined operating loss from continuing and discontinued operations of $1,531,820. From continuing operations alone, the loss was $865,005 and from discontinued operations, $666,815.

The balance sheet at 31 December 2025 is markedly bare. Total assets of $460,888 comprise primarily cash of just $1,872, trade and other receivables of $68,445, a refundable tax (R&D) asset of $190,571, and a $200,000 short-term loan advanced to Uscom Australia Pty Ltd (the newly standalone entity funded to begin operations). Total liabilities of $278,088 are largely trade payables ($256,995) and the remaining related-party loan balance of $21,093. Net assets were $182,800, recovering from negative net assets of ($38,224) at 30 June 2025.

Critically, the financial statements have been prepared on a basis other than going concern — a highly significant accounting disclosure. The basis of preparation reflects that Uscom is expected to be wound up within 12 months of the issuance of the report (27 February 2026), unless a suitable acquisition can be completed and the ASX lifts the trading suspension.

The Shell Strategy: What Happens Next?

Despite the severity of the current situation — suspended from trading, virtually no cash, no operating business — Uscom's management has articulated a clear strategic path. The company intends to remain listed on the ASX and actively seek a suitable acquisition of a business of similar nature to preserve continuity of operations and shareholder value.

The directors' report states the intention to: have the ASX lift the suspension once the relevant ASX Listing Rules are met; ultimately acquire a viable business; and preserve all current shareholdings so that shareholders have the opportunity to dispose of, retain, or increase their holdings when trading resumes.

This is a well-understood pathway in the ASX small-cap ecosystem, commonly referred to as a "backdoor listing" or "reverse takeover." The listed shell — in this case Uscom, with its ASX listing and 260,147,121 ordinary shares on issue — retains value as a vehicle for a private company seeking public market access without the cost and complexity of a full initial public offering. The two-year window granted by the ASX provides the time frame within which management must identify, negotiate, and complete such a transaction.

The NTA backing per ordinary share has fallen to 0.1 cents at 31 December 2025 (from 0.8 cents at 31 December 2024), reflecting the thin asset base remaining after the subsidiary disposal.

Uscom's Technology Legacy and the Medical Device Context

Even as Uscom the corporate entity undergoes restructuring, the underlying technology that the company developed and commercialised remains clinically relevant. Non-invasive haemodynamic monitoring is a growing area of medical practice, supported by evidence that early and accurate identification of haemodynamic compromise improves patient outcomes in sepsis, heart failure, and other critical conditions. The USCOM device and related products occupied a niche in this market characterised by their portability, ease of use, and applicability across diverse clinical settings.

The acquisition of Uscom's subsidiaries by AXO Medtech VCC suggests that the commercial and clinical value of these operations was recognised by a buyer willing to assume the liabilities associated with the business. The future development of Uscom's former technology and customer base now lies with AXO.

Leadership and Governance

Uscom's board throughout the half-year period consisted of Professor Rob Phillips (Chairman), Mr Christian Bernecker, Mr Brett Crowley, and Mr Xianhui Meng. The company's auditor is BDO Audit Pty Ltd, with Tina Han serving as the lead review director, who issued the independence declaration for the half-year ended 31 December 2025. BDO's review report contains an emphasis of matter paragraph drawing attention to the non-going concern basis of preparation — standard practice in such circumstances.

Investment and Shareholder Considerations

For existing Uscom shareholders, the current situation is unusual but not unprecedented in the ASX small-cap space. The shares are suspended, trading is not possible, and the company's primary value is its listed shell — the platform upon which management hopes to complete a reverse takeover transaction. Shareholders retain their entitlement to whatever value emerges from this process, whether that is a successful acquisition, a distribution of remaining assets, or ultimately a wind-down if no suitable acquisition can be identified.

The two-year ASX window expiring September 2027 is the key timeline. Management's track record, the quality of any acquisition target identified, and the prevailing appetite of the capital markets for the resulting business will determine whether Uscom's listed shell is converted into a new operating entity of value to shareholders.

Uscom completed the sale of all operating subsidiaries for $2.59 million, eliminating related-party debt and becoming a listed shell. Despite a disposal gain, the company remains ASX-suspended and prepared accounts on a non-going concern basis. Management now seeks a reverse takeover within a two-year compliance window ending September 2027.

FAQs

  1. Why did Uscom sell all subsidiaries?
    The sale extinguished related-party debt and transferred all operating businesses, effectively converting the company into a listed shell.
  2. Why is Uscom suspended from ASX trading?
    The ASX cited inadequate financial condition under Listing Rule 12.2 following an auditor disclaimer of opinion.
  1. What happens next for shareholders?
    Management intends to pursue a reverse takeover or acquisition before September 2027 to preserve listing status and shareholder value.